Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy
Conditions
Interventions
ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol)
Placebo
+1 more
Locations
73
United States
University of Alabama
Birmingham, Alabama, United States
Southern California Research Center
Coronado, California, United States
Catherine Frenette
La Jolla, California, United States
Stanford University
Palo Alto, California, United States
University of California at San Diego Moores Cancer Center
San Diego, California, United States
Pacific Medical Center
San Francisco, California, United States
Start Date
July 1, 2011
Primary Completion Date
July 1, 2015
Completion Date
July 1, 2015
Last Updated
September 6, 2019
NCT07175441
NCT05969860
NCT06427941
NCT05842174
NCT07164313
NCT07118202
Lead Sponsor
Polaris Group
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions